Neuronal Energy Metabolism Peptides in Canada: A Research Guide to ATP Demand, Lactate Shuttling, Mitochondria, Semax, SS-31, NAD+, and MOTS-c

Why neuronal energy metabolism needed its own cognitive peptide guide#

Northern Compound already covers mitochondrial peptides, cognitive peptide biomarkers, neurovascular coupling, glymphatic clearance, synaptic plasticity, excitotoxicity, and broad cognitive peptide sourcing in Canada. Those articles touch energy metabolism from different angles. What was missing was an energy-first guide: how should Canadian readers evaluate peptide claims when the actual question is whether neurons, astrocytes, endothelial cells, or mitochondria can meet cognitive energy demand under stress?

That gap matters because "brain energy" is one of the easiest phrases to abuse. A supplier page can cite mitochondrial biology and imply sharper thinking. A paper can show less oxidative stress and be repeated as if it proves better cognition. A peptide can change sleep, locomotion, appetite, stress behaviour, or vascular tone and be described as improving mental energy. Those are different claims.

Neurons are energy-expensive cells. Maintaining ion gradients, recycling neurotransmitters, restoring membrane potential after firing, supporting synaptic vesicle cycling, regulating calcium, and remodelling synapses all require ATP. But neuronal energy metabolism is not isolated inside the neuron. Astrocytes buffer neurotransmitters and can traffic lactate. Endothelial cells and pericytes shape blood-flow delivery. Microglia can shift inflammatory metabolism. Oligodendrocytes support axons. Sleep-wake state changes both demand and clearance. A peptide article that treats all of that as generic "energy support" is not useful.

This guide is written for Canadian readers evaluating non-clinical, research-use-only materials, endpoint logic, supplier documentation, and cautious evidence language. It does not provide medical advice, neurological guidance, treatment guidance, fatigue guidance, intranasal-use guidance, injection guidance, compounding instructions, dosing, route selection, or personal-use recommendations. Fatigue, cognition, neurodegeneration, injury, sleep, and metabolism terms appear only because they are common in published model systems and supplier claims that need careful interpretation.

The short answer: measure the energy layer before making a cognition claim#

A defensible neuronal-energy project starts by naming the bottleneck. Is the model testing glucose entry, glycolytic flux, lactate transfer, mitochondrial respiration, ATP buffering, redox stress, NAD turnover, calcium-linked energy demand, cerebral blood-flow delivery, synaptic workload, sleep-state recovery, or behavioural performance? Each layer changes the peptide shortlist and the claim boundary.

Within the current Northern Compound product map, SS-31 is the clearest live ProductLink when the model involves mitochondrial membrane stress, cardiolipin context, respiration, or oxidative phosphorylation. NAD+ fits when the hypothesis names redox state, PARP demand, sirtuins, CD38, or NAD-consuming stress pathways. MOTS-c belongs when AMPK-adjacent metabolic signalling, mitochondrial-derived peptide biology, or systemic energy allocation is part of the model. Semax is relevant when neurotrophic, plasticity, stress-injury, or attention-like endpoints intersect with energy demand. Selank and DSIP are narrower comparators when stress state or sleep architecture could explain an apparent energy result.

Those links are documentation checkpoints for research-use-only materials. They are not evidence that any material treats fatigue, improves focus, increases ATP in people, reverses cognitive decline, optimises mitochondria, or belongs in personal use.

Brain energy biology in one cautious map#

The adult brain uses a large share of resting energy relative to its mass, and much of that demand is tied to synaptic signalling rather than simple cell survival. Restoring sodium and potassium gradients after action potentials, loading synaptic vesicles, clearing glutamate, cycling neurotransmitter precursors, regulating calcium, and maintaining membrane potentials all impose energetic cost. Reviews of brain energy metabolism emphasize that neural computation and metabolic supply are tightly coupled rather than separate systems (PMC3900881; PMID: 25984033).

That coupling is why cognitive peptide claims need more than behaviour. A maze task, attention measure, or memory readout can change because of motivation, locomotion, anxiety-like state, sleep, pain sensitivity, sensory function, appetite, temperature, or drug-like stimulation. It can also change because the circuit genuinely handled energetic demand better. The difference is not visible without metabolic and circuit endpoints.

Astrocytes are central to the energy map. They sit near synapses and blood vessels, take up glutamate, regulate ions, store glycogen, and can produce lactate. The astrocyte-neuron lactate shuttle literature argues that activity-dependent astrocyte glycolysis and lactate transfer can support neuronal demand in certain contexts (PMID: 23973244; PMID: 29765021). The details remain model-dependent, but the practical lesson is stable: lactate is not just waste, and a brain-energy study should identify which cell type is producing, transporting, or using it.

Mitochondria add another layer. Neuronal mitochondria supply ATP, buffer calcium, shape reactive oxygen species, influence apoptosis pathways, and interact with axonal transport and synaptic vesicle cycling. Mitochondrial stress can make a synapse vulnerable even when gross cell viability looks normal. But a mitochondrial signal is not automatically a cognition signal. A peptide can improve respiration in cultured cells without improving circuit function. It can lower ROS by reducing activity, harming cells, or interfering with an assay. It can preserve ATP while altering neurotransmission in a way that matters for behaviour.

SS-31: mitochondrial membrane context needs respiration and synapse controls#

SS-31, also known as elamipretide in regulated-development literature, is a mitochondria-targeted tetrapeptide discussed around cardiolipin interaction, inner-membrane stability, oxidative phosphorylation, and oxidative stress. Northern Compound covers it in the SS-31 Canada guide, mitochondrial peptides, oxidative-stress peptide research, and mitophagy peptide research.

SS-31 is coherent in neuronal energy metabolism research when the model names mitochondrial membrane stress as the bottleneck. That might involve impaired oxidative phosphorylation, reduced spare respiratory capacity, cardiolipin disruption, calcium-linked mitochondrial load, axonal mitochondrial transport, or synaptic vulnerability under oxidative stress. In those settings, a mitochondria-targeted peptide can be a useful probe.

The interpretation risk is calling every mitochondrial result cognitive support. A lower ROS readout may reflect less oxidative stress, lower cell activity, fewer viable cells, altered dye loading, assay interference, or timing. A higher ATP signal may be meaningful, but it may also be disconnected from synaptic function. A better SS-31 energy panel would include oxygen-consumption rate, extracellular acidification rate, ATP-linked respiration, spare respiratory capacity, mitochondrial membrane potential, ROS with orthogonal methods, calcium handling, cell viability, synaptic markers, and electrophysiology where possible.

Material documentation matters because mitochondrial assays are sensitive to handling. Researchers should inspect lot-specific HPLC purity, mass or identity confirmation, fill amount, batch number, storage guidance, solubility notes, vehicle compatibility, and RUO labelling. A mitochondrial endpoint is not interpretable if the material was degraded, misidentified, contaminated, or handled outside a controlled research workflow.

NAD+: redox currency is not a universal energy claim#

NAD+ sits in the cognitive and anti-ageing research map because NAD biology intersects with redox reactions, sirtuins, PARPs, CD38, mitochondrial function, inflammatory metabolism, DNA-damage response, and cellular energy demand. Reviews describe NAD metabolism as a network of compartment-specific pools and enzyme systems rather than a single fuel gauge (PMC7963035; PMID: 32303694).

In neuronal energy research, NAD+ is relevant when the protocol states which NAD-dependent layer is under study. Is oxidative stress changing the NAD+/NADH ratio? Is DNA damage increasing PARP activity? Is sirtuin signalling part of a mitochondrial adaptation? Is CD38-driven NAD consumption involved in inflammatory ageing? Is the measured NAD pool neuronal, astrocytic, microglial, endothelial, or mixed tissue? Without those details, an NAD result becomes a slogan.

The main overreach is treating NAD+ as a direct cognitive energy product. A higher measured NAD pool does not automatically prove more ATP, better synaptic function, improved memory, or resilience in people. Mixed tissue measurements are especially easy to overread because a homogenate can hide opposing changes across neurons, astrocytes, microglia, endothelial cells, and infiltrating immune cells.

A stronger NAD+ energy study would pair NAD+/NADH and NADP+/NADPH readouts with ATP/ADP ratio, mitochondrial respiration, glycolytic flux, oxidative damage markers, PARP or sirtuin context, cell-type markers, and functional circuit endpoints. It would also specify the exact material under test. NAD+ supplier material is not interchangeable with every NAD precursor, derivative, supplement, topical, or clinical protocol discussed online.

For Canadian RUO sourcing, exact identity is non-negotiable. The checklist should include a current COA, identity confirmation, purity method, batch number, fill amount, storage and light-sensitivity guidance, and clear research-use-only positioning. A tracked product link lets readers inspect documentation. It does not imply personal use, clinical benefit, or cognitive enhancement.

MOTS-c: metabolic signalling belongs in context, not cognition shorthand#

MOTS-c is a mitochondrial-derived peptide discussed around metabolic stress signalling, AMPK-adjacent pathways, insulin sensitivity models, exercise context, and systemic energy allocation. Northern Compound covers it in the MOTS-c Canada guide, insulin-sensitivity peptide research, mitochondrial peptides, and nutrient-sensing peptide research.

MOTS-c belongs in neuronal energy metabolism only when the study has a metabolic-signalling reason. For example: does systemic metabolic stress change brain energy availability? Does AMPK-linked signalling alter neuronal resilience under nutrient stress? Does exercise-like signalling affect mitochondrial adaptation, inflammatory tone, or neurovascular supply? Those are plausible research questions. They are not the same as saying MOTS-c is a nootropic.

The cell-type problem is important. A systemic metabolic signal may change muscle, liver, adipose tissue, immune cells, vasculature, and brain compartments at the same time. A behavioural change could reflect peripheral metabolism, activity level, body weight, temperature, stress, sleep, or appetite before it reflects neuronal ATP. A brain-specific claim needs brain-specific endpoints.

A useful MOTS-c cognitive-energy panel might include AMPK phosphorylation, mitochondrial respiration, glucose uptake, lactate, inflammatory markers, neurovascular readouts, activity monitoring, body-composition controls if relevant, and region-specific brain markers. If the project claims synaptic or cognitive relevance, add synaptic proteins, electrophysiology, and behavioural confound controls. Keep the conclusion anchored to the measured layer.

Semax: neurotrophic and attention-like endpoints can change demand#

Semax is an ACTH(4-10)-derived peptide discussed around neurotrophic signalling, stress-injury context, monoamine systems, plasticity, and cognitive models. Northern Compound covers it in the Semax Canada guide, Selank vs Semax comparison, synaptic plasticity peptide research, and neurotrophic signalling peptide research.

In an energy-metabolism article, Semax is relevant because plasticity is metabolically expensive. BDNF, CREB, NGF context, dendritic-spine turnover, neurotransmitter cycling, and attention-like task engagement can all change energy demand. A model that shifts plasticity or arousal may alter glucose use, lactate dynamics, mitochondrial respiration, or blood-flow coupling. But that does not prove Semax directly increases ATP or optimises brain energy.

A strong Semax energy design would measure the plasticity layer and the metabolic layer together. Useful pairings include BDNF or CREB markers with ATP/ADP ratio, lactate, glucose uptake, mitochondrial respiration, synaptic markers, electrophysiology, and neurovascular measures. Behavioural tests need locomotor, anxiety-like, sensory, arousal, and sleep controls before being described as cognition.

Canadian RUO sourcing adds the usual reagent-quality layer: sequence clarity, lot-specific HPLC purity, identity confirmation, fill amount, batch number, storage guidance, and research-use-only labelling. Intranasal claims are common online, but this guide does not provide route guidance or personal-use advice. The research question is material documentation and endpoint interpretation, not use instructions.

Selank and DSIP: stress and sleep can masquerade as energy effects#

Selank and DSIP are included here as confound-control compounds rather than primary energy-metabolism peptides. Selank is discussed around stress response, cytokine tone, and anxiety-like behaviour. DSIP is discussed around sleep architecture and arousal-state research. Northern Compound covers these lanes in the Selank Canada guide, DSIP Canada guide, stress-resilience peptides, and sleep architecture peptide research.

Stress and sleep state can strongly alter apparent cognitive energy. A stressed animal may perform poorly because of arousal, freezing, avoidance, sleep disruption, appetite change, or altered locomotion. A sleep-shifted model may show different memory consolidation, glymphatic timing, inflammatory tone, and synaptic homeostasis. If a peptide changes those states, a cognitive task can improve or worsen without any direct neuronal ATP mechanism.

That does not make Selank or DSIP irrelevant. It means the protocol should name them properly. Selank is coherent when stress physiology, cytokine context, or HPA-axis state is part of the energy hypothesis. DSIP is coherent when sleep timing, arousal, or slow-wave context could change metabolic recovery. Neither should be described as improving brain energy unless metabolic endpoints move in a way that survives confound controls.

What to measure before making an energy-metabolism claim#

ATP demand and ATP supply#

ATP/ADP ratio, phosphocreatine context, ATP-linked respiration, and energy-charge calculations can help locate supply-demand balance. But ATP is dynamic and compartmentalised. A bulk tissue ATP measure may miss synaptic, axonal, astrocytic, or mitochondrial microdomain changes. Time point matters, especially after stimulation, injury, hypoxia, glucose shift, or sleep disruption.

Mitochondrial respiration#

Seahorse oxygen-consumption rate can separate basal respiration, ATP-linked respiration, proton leak, maximal respiration, and spare capacity. It is useful, but it is not self-interpreting. Cell density, viability, substrate choice, plating stress, media composition, oxygen conditions, and normalisation can all distort the result. Pair respiration with viability, protein or cell counts, mitochondrial mass, membrane potential, and functional endpoints.

Glycolysis and lactate#

Extracellular acidification rate, lactate concentration, glucose uptake, GLUT1/GLUT3, hexokinase activity, and glycogen context can map glycolytic contribution. Lactate should be interpreted by cell type and state. Increased lactate can reflect useful astrocyte-neuron transfer, hypoxia, excessive glycolysis, mitochondrial impairment, high neuronal activity, or cell stress. Transporter markers such as MCT1, MCT2, and MCT4 can help locate the direction of movement.

Redox state#

ROS, glutathione, NAD+/NADH, NADP+/NADPH, lipid peroxidation, protein carbonyls, 8-OHdG, and antioxidant-response markers can describe oxidative context. Avoid one-dye conclusions. Many fluorescent redox probes are sensitive to loading, light, pH, mitochondrial membrane potential, cell number, and assay interference. A lower ROS signal is useful only when the protocol shows cells are alive, active, and comparable.

Calcium and synaptic workload#

Calcium handling links neural activity to mitochondrial demand. A peptide can look favourable by reducing excitatory load, improving buffering, or suppressing activity. Those are not equivalent. Pair calcium imaging or electrophysiology with synaptic markers such as PSD-95, synaptophysin, VGLUT1, VGAT, receptor trafficking, and plasticity assays. If the model involves glutamate stress, connect this article back to excitotoxicity peptide research.

Neurovascular delivery#

Energy supply depends on blood flow and oxygen delivery in tissue models. Neurovascular coupling, endothelial function, pericyte behaviour, nitric-oxide signalling, capillary density, and oxygenation can change the metabolic interpretation. If a peptide alters performance through delivery rather than mitochondrial efficiency, the conclusion should say that. Northern Compound's neurovascular coupling guide covers this layer in detail.

Model selection: what each system can prove#

Cultured neurons are useful for narrow mitochondrial, calcium, synaptic, and survival questions. They cannot prove brain-level energy delivery, sleep-state recovery, or cognition. Pure neuronal cultures also remove astrocytes, microglia, oligodendrocytes, and vascular cells that often determine energy context.

Neuron-astrocyte co-cultures can test lactate, glutamate uptake, glycogen context, and metabolic support more realistically. They still simplify blood flow, immune context, myelination, and tissue architecture. Cell ratios and maturation state matter.

Brain slices preserve some circuitry and cell-type relationships. They support electrophysiology, mitochondrial dyes, lactate sensors, oxygen context, and pharmacological stimulation. They are sensitive to slice health, oxygenation, glucose concentration, temperature, and time after preparation.

Organoids and assembloids can model development and multicellular interactions, but they often have immature metabolism and limited vascular delivery. Energy claims from organoids require careful oxygen, nutrient, cell-type, and necrotic-core controls.

In vivo models can connect behaviour, blood flow, sleep, stress, and tissue endpoints. They also add confounds. Activity level, body weight, appetite, thermoregulation, pain, sensory function, stress, sex, age, microbiome, and circadian timing can all change cognitive-looking outcomes. A strong in vivo design measures behaviour and tissue biology rather than letting one substitute for the other.

How to separate energy support from stimulation#

One of the harder interpretation problems in cognitive-energy research is separating genuine energetic resilience from stimulation. A model can look more energetic because the organism moves more, explores more, sleeps less, startles more, eats differently, or shows altered anxiety-like behaviour. That may be interesting, but it is not the same as improved neuronal ATP handling.

A stimulation-like signal usually appears first in behaviour: increased locomotion, altered open-field exploration, reduced immobility, changed reward seeking, changed sleep timing, or changed appetite. Those outputs can improve one cognitive task and worsen another. They can also increase neuronal energy demand rather than improve supply. If a peptide makes a model more active, the tissue may need more ATP, more glucose, more blood flow, and more heat dissipation. Calling that brain-energy support without measuring supply and demand reverses the logic.

A genuine energetic-resilience claim is narrower. It shows that under a defined challenge, the system preserved ATP-linked respiration, maintained membrane potential, reduced damaging redox stress without suppressing activity, supported synaptic function, or restored metabolic flexibility while viability and activity controls remained intact. In tissue or animal models, it should also check whether oxygen delivery, vascular response, and sleep state changed. Otherwise the energy signal may be secondary to arousal, vascular tone, or reduced workload.

This distinction matters for Semax, Selank, and DSIP because cognitive, stress, and sleep endpoints can change performance before any mitochondrial mechanism is proven. It also matters for MOTS-c because systemic metabolic changes can alter activity and body-state variables. For SS-31 and NAD+, the risk is different: biochemical plausibility can make a mitochondrial or redox result sound more behaviourally important than the data allow.

A clean study therefore pre-registers the main claim layer in plain language. If the claim is mitochondrial, behaviour is secondary. If the claim is cognitive, metabolism is only one candidate mechanism. If the claim is stress-state correction, do not label it energy metabolism unless energy endpoints moved. If the claim is sleep-state recovery, measure sleep architecture rather than assuming rest equals repair.

A practical endpoint stack for Canadian labs#

A useful endpoint stack does not need every assay. It needs enough layers to prevent one measurement from carrying the whole claim. For a cell model, the minimum stack might include viability, ATP/ADP ratio, oxygen-consumption rate, extracellular acidification rate, lactate, mitochondrial membrane potential, ROS by at least two methods, and peptide-stability controls. If the model is neuronal, add calcium handling and at least one synaptic marker. If astrocytes are involved, add GFAP or other astrocyte-state markers, glutamate uptake context, glycogen context where relevant, and MCT transporters.

For a slice or tissue model, add oxygenation, stimulation state, electrophysiology, regional specificity, and histology. Hippocampus, cortex, striatum, retina, spinal cord, and white matter can show different energy vulnerabilities. A peptide signal in one region should not be generalised across the nervous system without support. If the study claims memory relevance, hippocampal or cortical endpoints need to match the behavioural task rather than being sampled wherever tissue was convenient.

For an in vivo cognitive-energy project, a stronger stack includes activity monitoring, sleep or circadian timing, body weight, food intake, temperature, stress-state controls, sex and age reporting, task-specific sensory checks, tissue metabolic endpoints, and material documentation. If a model uses injury, inflammation, hypoxia, glucose stress, or sleep deprivation, the challenge itself should be characterised. Otherwise the peptide may look favourable only because the baseline injury was inconsistent.

The reporting standard should be modest. A good result might say that a specific peptide preserved spare respiratory capacity in a defined model, shifted lactate handling in an astrocyte-neuron co-culture, or changed NAD+/NADH under a specific stressor. That is enough. It does not need to become a broad cognition claim. Narrow claims compound trust because they let readers see exactly where the evidence starts and stops.

Storage, handling, and assay-interference issues that matter more here#

Energy-metabolism assays punish sloppy handling. Peptides that look acceptable in a simple purity screenshot can still create problems in mitochondrial and redox workflows. Oxidation, adsorption to plastic, repeated freeze-thaw cycles, pH drift, solvent carryover, residual salts, endotoxin, and concentration error can all show up as altered respiration, altered ROS, or changed viability. The problem is not just whether the peptide is "pure". The problem is whether the material and vehicle behave cleanly under the assay conditions.

SS-31-style mitochondrial work should pay attention to storage, light exposure, membrane-affinity context, and concentration-response shape. A U-shaped or toxic response can be misread if only one concentration is tested. NAD+ work should account for degradation, light sensitivity, exact identity, and the difference between extracellular material, intracellular pools, and downstream metabolites. MOTS-c work should treat systemic metabolic context as part of the model rather than a nuisance variable. Semax and Selank work should be especially cautious when behavioural or stress endpoints are used to infer energy mechanisms.

Assay interference is not theoretical. Fluorescent redox probes can be altered by pH, membrane potential, dye loading, light exposure, cell number, and direct chemical interactions. ATP assays can be affected by cell lysis efficiency and viability. Lactate assays can be influenced by media composition and timing. Seahorse experiments can be distorted by plating density, edge effects, substrate choice, and normalisation. A serious peptide study includes vehicle controls, positive and negative controls, concentration-response testing, viability checks, and at least one orthogonal endpoint.

For readers evaluating suppliers, this is why COA language has to connect to experiment quality. A current lot-specific COA does not prove a peptide will produce a favourable result. It only reduces one avoidable source of ambiguity. In energy research, that reduction matters because the signal can be subtle and the assays can be noisy.

Canadian RUO sourcing checklist for energy-metabolism studies#

Energy-metabolism endpoints are sensitive to material quality. Small differences in purity, counterions, residual solvent, endotoxin, oxidation, storage, concentration, or vehicle can change mitochondrial and redox assays. A supplier page is not enough.

Before interpreting any peptide result, Canadian readers should look for:

• lot-specific HPLC purity rather than generic purity language;
• identity confirmation, ideally mass-based where appropriate;
• sequence clarity and exact compound naming;
• batch number and fill amount;
• storage temperature, light sensitivity, and reconstitution constraints where relevant;
• RUO-only labelling and avoidance of disease-treatment or personal-use claims;
• endotoxin awareness for immune-sensitive or mitochondrial-sensitive assays;
• vehicle controls and peptide-recovery checks when binding, oxidation, adsorption, or degradation is plausible.

SS-31, NAD+, MOTS-c, Semax, Selank, and DSIP should be treated as reagent-documentation starting points, not as personal-use recommendations. The same is true for any Canadian supplier comparison or store link on Northern Compound.

Claim boundaries that keep the article honest#

A cautious neuronal-energy claim says what changed, where, and under which model conditions. For example: "SS-31 shifted spare respiratory capacity in stressed neuronal cultures with preserved viability" is a narrow metabolic claim. "SS-31 improves brain energy" is too broad. "NAD+ altered mixed-tissue NAD+/NADH after injury" is a biochemical claim. "NAD+ restores cognition" is a clinical claim unless the evidence actually supports it. "Semax changed task performance and BDNF markers" is not proof of ATP support without metabolic data.

The same standard applies to null or mixed findings. If a peptide improves respiration but does not change synaptic function, the honest conclusion is mitochondrial support in that model, not cognitive rescue. If behaviour improves while ATP and respiration do not move, the better hypothesis may be stress, arousal, sleep, motivation, or task performance. If redox markers improve while lactate and electrophysiology worsen, the result may indicate suppressed activity rather than healthier metabolism. Mixed results are not failures; they are often the point of doing layered endpoint work.

Canadian readers should also watch for time-course mismatches. Energy metabolism can shift within minutes, while synaptic remodelling, inflammatory state, sleep recovery, and behavioural learning can unfold over hours or days. A peptide may produce an early metabolic signal that disappears before behaviour is tested, or a delayed adaptation that is missed by an early assay. Strong articles and supplier-adjacent claims state timing clearly instead of collapsing every endpoint into one mechanism.

Finally, the language should keep the research-use-only frame visible. "Relevant to mitochondrial stress models" is acceptable when the evidence supports it. "Supports mental energy" is a consumer wellness claim. "Changed lactate handling in a co-culture" is a research claim. "Boosts brain fuel" is marketing. The difference matters because Northern Compound is meant to help readers evaluate evidence and documentation, not dress weak claims in scientific vocabulary.

The strongest Northern Compound style is simple: separate mechanism, endpoint, model, material quality, and user-facing interpretation. Do not turn a reagent into a therapy. Do not turn a cell result into a human outcome. Do not turn a behaviour change into a mechanism. Do not turn a COA into efficacy evidence.

FAQ#

Bottom line#

Neuronal energy metabolism is a useful cognitive research lens only when it stays specific. The question is not whether a peptide sounds energising. The question is which biological layer changed: delivery, glycolysis, lactate shuttling, mitochondrial respiration, redox state, NAD turnover, synaptic workload, vascular coupling, sleep-state recovery, or behaviour.

For Canadian RUO readers, SS-31, NAD+, MOTS-c, Semax, Selank, and DSIP can all appear in a neuronal-energy map, but each belongs to a different hypothesis. The article stays honest when the endpoint, model, material quality, and claim boundary stay visible.

That is the difference between research guidance and metabolism-themed marketing.